<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sarcoma</journal-id><journal-id journal-id-type="publisher-id">SRCM</journal-id><journal-title>Sarcoma</journal-title><issn pub-type="ppub">1357-714X</issn><issn pub-type="epub">1369-1643</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19266050</article-id><article-id pub-id-type="pmc">2650184</article-id><article-id pub-id-type="doi">10.1155/2008/874075</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sorensen</surname><given-names>Flemming Brandt</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Jensen</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vaeth</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hager</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Funder</surname><given-names>Anette Mariane Daa</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Safwat</surname><given-names>Akmal</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Keller</surname><given-names>Johnny</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Christensen</surname><given-names>Mariann</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>University Institute of Pathology, Aarhus University Hospital, Aarhus Sygehus, THG, 8000 Aarhus, Denmark</aff><aff id="I2"><sup>2</sup>Department of Oncology, Aarhus University Hospital, Aarhus Sygehus, NBG, 8000 Aarhus, Denmark</aff><aff id="I3"><sup>3</sup>Department of Biostatistics, University of Aarhus, 8000 Aarhus, Denmark</aff><aff id="I4"><sup>4</sup>Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus Sygehus, NBG, 8000 Aarhus, Denmark</aff><author-notes><corresp id="cor1">*Flemming Brandt Sorensen: <email>fbs@dadlnet.dk</email></corresp><fn fn-type="other"><p>Recommended by Kees Verhoef</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>874075</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Flemming Brandt Sorensen et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Purpose</italic>. To investigate angiogenesis, multiple drug resistance (MDR) and proliferative activity as prognostic variables in patients suffering from osteosarcoma. <italic>Methods</italic>. Histologic biopsies from 117 patients treated in the period from 1972 through 1999 were immunohistologically investigated regarding angiogenesis (CD34), proliferative activity (MIB-1), and the expression of p53 and MDR (P-glycoprotein (Pgp); clones JSB-1, C494, and MRK16). Quantitative and semiquantitative scores of immunoreactive cells were analyzed statistically along with retrospectively obtained clinicopathologic variables.<italic>Results</italic>. Chemotherapy reduced the rate of amputations (<italic>P</italic> = .00002). The Pgp was overexpressed  (score &#x02265;2) in 48% of the primary, diagnostic biopsies, and high Pgp correlated with high Pgp in postsurgical specimens (<italic>P</italic> = .003). In contrast, no such associations were disclosed for estimates of angiogenesis (<italic>P</italic> = .64) and p53 (<italic>P</italic> &#x0003e; .32), whereas the MIB-1 index was reduced in the post-chemotherapy specimens  (<italic>P</italic> = .02).The overall, disease-specific survival was 47%, increasing to 54% in patients receiving pre-operative chemotherapy. Statistical analyses showed prognostic impact exclusively by patient age and type of osteosarcoma.<italic>Discussion</italic>. The studied series of patients documented already prior to the chemotherapy era, a rather excellent survival and estimates of angiogenesis, proliferation, p53, and Pgp expressions, did not demonstrate sufficient power to serve as predictors of treatment response or survival.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>The treatment of patients with osteosarcomas has during the last twodecades changed from a solely surgical approach to a highly complex multimodaltherapy with preoperative chemotherapy as the dominating innovation. Prior to the chemotherapy era, the studies addressing survival of patients withosteosarcoma have, among others, identified morphological type of tumor, siteof tumor, tumor stage and size, and duration of symptoms as prognosticvariables of relevance [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. Investigations including large patientpopulations treated after the introduction of preoperative chemotherapyprotocols have evidenced a shift toward histological response to chemotherapy as the mostinformative prognostic parameter [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>], a conclusive finding also corroborated by meta-analysis [<xref ref-type="bibr" rid="B6">6</xref>] and large-scale studies [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Although the treatment outcome forpatients with osteosarcoma has improved significantly regarding survival afterthe introduction of preoperative chemotherapy, it is still difficult to optimizethe therapy offered to the individual patient in that the most importantprognostic variable cannot be evaluated precisely until after surgicalintervention. The extent of tumor necrosis can be guided by various imagescans, but first after completion of preoperative chemotherapy, objectivemeasures in the histopathological examination of the surgical specimen are ableto estimate the true extent of chemotherapy-induced tumor necrosis [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>].</p><p>Attempting to get around thisobstacle, researchers have focused their investigations on the characteristicsof the primary, diagnostic biopsy from patients with osteosarcomas. Featureslike proliferation rate [<xref ref-type="bibr" rid="B10">10</xref>], <italic>P53</italic> gene alteration [<xref ref-type="bibr" rid="B11">11</xref>], and especially, multiple drug resistance (MDR) [<xref ref-type="bibr" rid="B12">12</xref>] have been examined. Findings regarding prediction of chemotherapeuticallyinduced tumor necrosis have, however, been rather contradicting, and thusdifficult to implement in a routine diagnostic setting of osteosarcoma. Moreover, recent results from a randomized phase III trial of the <italic>European Osteosarcoma Intergroup</italic> suggestthat intensified chemotherapy may improve histologic response but not survivalin osteosarcoma patients [<xref ref-type="bibr" rid="B13">13</xref>]. This questions the idea of using theextent of chemotherapeutically induced osteosarcoma necrosis as a surrogatemeasure of clinical outcome.</p><p>The development of new microvesselsin tumors, the so-called neoangiogenesis, has for some years been investigatedin a number of different types of neoplasms, and has indeed been shown to be ofprognostic significance in some. Estimating the level of angiogenesis in amalignant neoplasm is attractive for several reasons, and may reflect thecapacity for a malignant tumor to metastasize, and from the therapeutic pointof view, for developing antiangiogenetic drugs that may lead to starvation andultimately death of the tumor in question. The angiogenetic level may also beof interest in planning systemic chemotherapy, as it is the case for patientswith osteosarcomas, and it has accordingly also been investigated in suchneoplasms [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>].</p><p>In this retrospective study, we haveinvestigated the prognostic value of angiogenesis, proliferation rate, alterationsin p53 and MDR/P-glycoprotein (Pgp) expressions in osteosarcomas from patients treatedat the Sarcoma Center,Aarhus University Hospital, Denmark from1972 through 1999, using an immunohistochemical approach. The study thusincludes patients treated both before and after the introduction of preoperativechemotherapy, and provides an update of the treatment results in patients withosteosarcoma at Aarhus University Hospital.</p></sec><sec sec-type="section" id="sec2"><title>2. PATIENTS</title><p>The cohort of patients studied was retrospectivelyretrieved from the files of the University Institute of Pathology, Aarhus University Hospital, Denmark in the period from 1972 through 1999. This database was combined with the clinical database at the Department of Oncology, Aarhus University Hospital, Denmark, and a total of 134 consecutively admitted patients treated for primary,nonmetastatic osteosarcoma of the extremities and pelvis were identified. Mostof the patients had been referred to the Sarcoma Center of Aarhus UniversityHospital. Retrieval of clinical follow-up information and/or histologicalmaterial was unsuccessful in 17 cases, leaving a total of 117 patients for inclusioninto the investigation with at least 5 years of follow-up after primarytreatment.</p><p>The clinicopathological data of thestudied patients are summarized in <xref ref-type="table" rid="tab1">Table 1</xref>. Prior to 1984, the treatment ofosteosarcoma at the Sarcoma Center, Aarhus University Hospital  was limited to surgery, but after 1984, preoperative chemotherapy was offeredto all patients, followed by surgical treatment which has increasingly focused onlimb-salvage resections. In the early chemotherapy era, the MAP-regimen(mitomycin, adriamycin, and cisplatin) [<xref ref-type="bibr" rid="B19">19</xref>] wasused, based on <italic>Mayo Clinic</italic> experience. From 1991, the chemotherapy was changed to the <italic>European Osteosarcoma Intergroup Study</italic> approach, based ondoxorubicin and cisplatin [<xref ref-type="bibr" rid="B13">13</xref>]. A few patients received chemotherapy and/or radiation therapy alone or incombination (<xref ref-type="table" rid="tab1">Table 1</xref>), mostly as an adjuvant postoperative therapy at recurrentdisease, in that only very few patients refused surgery at primary treatment.</p><p>The clinical data were retrieved fromthe medical records. Patientswere seen at regular intervals as outpatients at the Department of Oncology, Aarhus University Hospital, or at admissionto this Department or the Department of Orthopaedic Surgery in the case of recurrence. Thus, any type of recurrence was added to the clinical records and to theclinical database, and in the case of death, the cause of death was establishedfrom autopsy records or from the death certificates. The investigation wasapproved by the Ethical Committee of Aarhus County (Project no. 1999/4601) and by the DanishData Registration Authorities (Danish Data Protection Agency, Project no. 2000-41-0174).</p></sec><sec sec-type="section" id="sec3"><title>3. MATERIAL AND METHODS</title><p>Primary, diagnostic tumor biopsies,formalin fixed, and paraffin embedded, from all 117 patients and tumorspecimens from the 112 patients, who underwent surgical treatment, wereavailable for investigation. One representative tissue block was selected fromeach case by screening all histological sections. In this way, 117 tissueblocks from primary, diagnostic biopsies, and 46 tissue blocks from surgicalresection specimens of patients receiving preoperative chemotherapy wereselected for the investigation. When possible, the tissue blocks were selectedfrom the soft tissue extensions of the osteosarcomas, in that this tissue hadunderwent none or only a short period of decalcification in either nitric acidor EDTA.</p><p>The surgical specimens from patientstreated with preoperative chemotherapy had been processed according tointernational guidelines of estimating the extent of chemotherapy-induced tumornecrosis [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. Briefly, the resected osteosarcoma was sawed along thelargest diameter of the tumor, and a slice of the surgical specimen wassubsequently decalcified and embedded in paraffin blocks in toto. All histological sections cut from each tissue block wereexamined and a semiquantitative estimate of overall tumor cell necrosis inpercent was reported. The tissue blocks used for further studies were carefullyselected to ensure vital tumor tissue, but in 6 cases with 100% tumor necrosis,no further investigations were performed.</p><sec id="subsec3.1"><title>3.1. Immunohistochemistry</title><p>Histologically,4 <italic>&#x003bc;</italic>m thick sections were cut from each tissue block, placed on coated slides, anddeparaffinized in xylene followed by ethanol. Endogenous peroxidase was blockedin methanol with H<sub>2</sub>O<sub>2</sub> (v/v 35%). Several experiments werecarried out to unmask epitopes, including various enzymatic treatments andbuffer baths in micro-oven, but the fragile, decalcified tissue sections mostlydetached from the histologic slides. The best results were obtained byimmersing the histologic slides in TEG buffer (pH 9.0) at 60&#x000b0;C in aheating cupboard for 72 hours, followed by sensibilization in TRIS buffer (pH7.6) and normal horse serum (DAKO, Glostrup, Denmark).</p><p>Incubation with primary antibodiesfor detecting proliferation (clone MIB-1, DAKO, Glostrup, Denmark), p53 (clone DO-7, DAKO, Glostrup, Denmark), and CD34 (clone QBend10, Immunotech, Quebec, Canada), diluted 1 : 200, 1 : 200,  and 1 : 100,  respectively, in antibody diluent (DAKO, Glostrup, Denmark) was performed overnight (18 hours), followed by rinsing in TRIS buffer. Secondary biotinylated antibody(PK-6200, Vector) was added for 1 hour, followed by TRIS buffer added 0.5% blockingreagent (DuPont TSAKit). To intensify the staining, the histologic sections were treated withtyramide (in TRIS buffer added H<sub>2</sub>O<sub>2</sub>) and rinsed in TRIS buffer. Avidin-biotin complex served as the tertiary antibody (PK-6200, Vector), withincubation for 1 hour followed by rinsing in TRIS buffer. Diaminobenzidine(DAB) was used as chromogen, and finally the histologic sections were counterstained in Mayer's hematoxyline and cover slipped in Aquatex. The tyramidesignal amplification (TSA) showed excellent results for staining with MIB-1 andp53, whereas it had no improvement on the staining for CD34, which was overallof rather poor quality with only 95 assessable biopsies out of a total of 163.</p><p>The immunohistological staining forMDR (Pgp) was carried out by employing three different monoclonal antibodies,clones JSB-1, C494 (Zymed Laboratories Inc., Calif, USA), and MRK16 (Alexis Biochemical, Lausen, Switzerland), diluted 1 : 20, 1 : 500,  and 1 : 400,  respectively. Visualization wasperformed by the Envision technique (DAKO, Glostrup, Denmark). Preliminary trials showed rather differentstaining results of individual biopsies with the 3 different antibodies, and accordinglyit was decided to perform the staining procedure of all cases with a primaryantibody cocktail containing all 3 clones, which has also been recommended byan international consensus report regarding detection of Pgp [<xref ref-type="bibr" rid="B20">20</xref>]. Allimmunohistochemical procedures were followed by negative controls, omitting theprimary antibody. For MIB-1, p53, and CD34, the tumor sections had an inbornpositive control, and sections from normal human kidney were used as positivecontrol for the Pgp staining.</p><p>There were no differences in thequality or scorability of the immunohistochemical stains, when comparingosteosarcomas included early or late in the nearly 30-year uptake period of the study.</p></sec><sec id="subsec3.2"><title>3.2. Scoring of MIB-1 and p53</title><p>The immunoreactions for both MIB-1and p53 are nuclear, but a few cases showed in addition a weak, cytoplasmicreaction, which did not, however, interfere with the morphometricquantification of the sections, in that the tyramide signal amplificationtechnique highly intensified the nuclear staining. The quantification of theMIB-1 and p53 immunoreactivity was carried out, using the same morphometricapproach, applying the computer-assisted CAST-grid system (Olympus, Denmark). At low magnification, the histological sections were projected onto a computerscreen, using a video camera. The computer software enables drawing around thetumor area (the so-called meander), and within this area, the computergenerates fields of vision at high magnification (1425X), with the first fieldgenerated at random, and the subsequent fields distributed systematicallywithin the meander area. A counting frame was superimposed on the histologicalimage, and using an unbiased, two-dimensional counting rule [<xref ref-type="bibr" rid="B21">21</xref>], thepositive and negative nuclear profiles were counted (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The ratio ofpositive to negative nuclear profiles was calculated in percent, and, moreover,the density index of positive nuclear profiles pr. mm<sup>2</sup> tumor areawas calculated. On the average, 50 fields of vision (range: 18&#x02013;103) wereinvestigated in each tumor (corresponding to a mean tumor area of about 80 mm<sup>2</sup>),with a mean of 140 counted nuclear profiles per case (range: 5&#x02013;542). The samplingfraction within the studied tumor sections ranged between 0.7% and 6.7%.</p></sec><sec id="subsec3.3"><title>3.3. Estimation of angiogenesis</title><p>The histological sections werescanned at low magnification to localize the three so-called <italic>hot spots</italic> with increasedmicrovascularity (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>). In each of these hot spots, the neoangiogenesiswithin the tumor tissue was quantified using the Chalkley technique [<xref ref-type="bibr" rid="B22">22</xref>],as recommended earlier [<xref ref-type="bibr" rid="B23">23</xref>]. This method uses a graticule, mounted inthe ocular of the microscope, with 25 randomly distributed points. At highmagnification (250X), the ocular was rotated until the highest number of these25 points superimposed on microvascular profiles in the tumor tissue (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). The mean of the three hot spot counts was reported as the angiogenetic Chalkleynumber. In cases with no obvious hot spots, the mean of three randomly selectedfields of vision within the tumor area represented the Chalkley number. Asmentioned above, the angiogenesis could not be scored in a large number ofcases because of a false negative immunostain. This is probably caused by aninherent defect in the studied tissue sections, may be due to acid exposureduring decalcification at the primary tissue processing, in that a lot ofmicrovascular profiles could be demonstrated morphologically.</p></sec><sec id="subsec3.4"><title>3.4. Scoring of MDR/Pgp</title><p>The scoring of Pgp immunostainingwas carried out on a semiquantitative scale, in accordance with earlier studiesperformed at the <italic>Rizzoli Clinic,</italic> Italy [<xref ref-type="bibr" rid="B12">12</xref>]: score 0 = complete absence of immunoreactive tumor cells; 1 = scattered, weakly immunoreactive tumor cells in less than 10% of thehistological specimen; 2 = diffuse, weakly immunoreactive tumor cells in morethan 10% of the tumor area; 3 = diffuse, intense immunopositivity in more than10% of the tumor cells. A Pgp score &#x02265;2 was considered to represent resistanceto chemotherapy [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. The heterogeneity of the Pgp immunostainwithin one tumor section, and among different tumor sections, was onlymoderate, with just a few cases showing marked variability in staining intensity,and the scoring was based on the highest degree of immunoreactivity within theexamined histological slides. Mostly, the Pgp positive cells showed a diffusecytoplasmic immunoreactivity, but in some cases, an enhanced membrane stainingwas visualized (<xref ref-type="fig" rid="fig3">Figure 3</xref>), as was reinforced immunoreactivity of the Golgiregion. Complete absence of Pgp-staining was only recorded in 13 specimens, andin one specimen the Pgp-reactivity could not be estimated because of recurrentdetachment of the histological section from the slide during processing.</p></sec></sec><sec sec-type="section" id="sec4"><title>4. STATISTICS</title><p>Associations between categoricalvariables were assessed by <italic>&#x003c7;</italic><sup>2</sup>-test or Fisher's exact test. Student's <italic>t-</italic>test was used for comparison ofcontinuous variables between groups of patients. A rang sum test was used ifthe variation in the data was poorly described by a normal distribution. Apaired <italic>t-</italic>test or McNemar's test was used for pre versus postcomparisons. Associations between continuous variables were assessed byPearson's correlation coefficient and Spearman's correlation coefficient fornonnormal data.</p><p>Survival times and time to relapsewere described by Kaplan-Meier plots and the prognostic evaluation of thevariables was performed by log rank tests; the continuous variables weredichotomized at the median. Patients were followed until death from disease, oruntil the latest clinical control at the closure of the study. A 5% level ofsignificance was used for all statistical tests.</p></sec><sec sec-type="section" id="sec5"><title>5. RESULTS</title><sec id="subsec5.1"><title>5.1. Clinicopathologic data</title><p>The obtained clinicopathological data are summarized in<xref ref-type="table" rid="tab1">Table 1</xref>. Seventy one (61%) and 46 patients (39%) date from the time before andafter the introduction of preoperative chemotherapy, respectively.</p><p>On the average, the diagnostic delaywas estimated to nearly half a year, but with a wide range, with 11 patientshaving a delay for more than one year. This may explain the fact that the vastmajority of osteosarcomas evidenced soft tissue extension at diagnosis, withonly 19% of the patients presenting with a tumor limited by cortical bone. Nineteen tumors (16%) represented other types of osteosarcomas, than the conventionalhigh-grade neoplasm. This group of patients showed a heterogeneous range ofmorphological types, including both small cell and telangiectaticosteosarcomas, and osteosarcomas of lower grade malignancy.</p><p>Five patients did not receivesurgical treatment, whereas 26 patients underwent limb-salvage surgery incombination with preoperative chemotherapy. The majority of the patients hadamputation which represents a reflection of secularity related to the retrospective design with patientstreated within a period of 27 years. Although histological evaluation of thesurgical specimens showed intralesional resection in 4 cases, the clinicalresponse to treatment was judged incomplete (persistent disease) in 10patients. However, the latter group includes also 5 patients, who did notreceive primary surgical treatment, whereas one patient was found to havemetastatic disease shortly after surgical treatment.</p><p>In <xref ref-type="table" rid="tab2">Table 2</xref>, the relationship betweenthe type of surgical treatment, documented by the histological examination ofthe surgical specimen, and the administration chemotherapy has been listed. There is a significant shift from amputations to surgical treatment by wideresections with the introduction of preoperative chemotherapy (<italic>P</italic> = .00002). Only 35% of the patients receiving this treatment modality had, however,excellent histologic response (&#x0003e;90% tumor necrosis).</p></sec><sec id="subsec5.2"><title>5.2. Quantitative variables</title><p>Results regarding angiogenesis,proliferation, and p53 expression are summarized in <xref ref-type="table" rid="tab3">Table 3</xref>. Separate analysis ofthese variables in the group of nonconventional osteosarcomas showed that theseparameters, on the average, were not statistically different from the resultsharvested from the investigated conventional osteosarcomas (.06 &#x0003c; <italic>P</italic> &#x0003c; .20). However, in this group, also including low-grade osteosarcomas, the angiogenesis,proliferation rate and index showed a tendency toward lower values (5.94, 43.2%,and 1565, resp.),whereas the p53 expression and p53 index showed a tendency toward higher values(74.17 and 3277, resp.).The elevated p53 scores were specifically caused by extremely high values ofthis parameter in a few round cell osteosarcomas included in this limited groupof patients.</p><p>Data on angiogenesis in bothpretreatment and posttreatment histological specimens were available in 25patients, and no statistically significant difference in the degree ofmicrovascularity was disclosed in the two series of biopsies (<italic>P</italic> = .64). Analysesamong the other quantitative variables investigated showed mostly nostatistically significant associations (<italic>P</italic> &#x0003e; .10), apart from variousassociations between estimates of proliferation and the p53 expression in thestudied osteosarcomas. Thus, estimates of the pre-chemotherapy p53 expressionwere inversely associated with both pre- and post-chemotherapy estimates ofproliferation (<italic>P</italic> &#x0003c; .04). On the other hand, estimates of thepost-chemotherapy p53 expression were positive associated with the sameestimates of tumor cell proliferation (<italic>P</italic> &#x0003c; .02). These associations,however, also are reflections of the decreased proliferation inpost-chemotherapy osteosarcomas (<xref ref-type="table" rid="tab4">Table 4</xref>), which was statistically significant regarding estimates of proliferation index (<italic>P</italic> = .02). Noassociations were detected between the quantitative variables and the largesttumor diameter (<italic>P</italic> &#x0003e; .12) or clinical parameters (<italic>P</italic> &#x0003e; .10).</p></sec><sec id="subsec5.3"><title>5.3. MDR/P-glycoprotein</title><p>A total of 60 primary, diagnosticbiopsies (52%) showed a Pgp score less than 2, and 56 biopsies (48%) expresseda score higher than 2, whereas one biopsy could not be evaluated. In the groupof nonconventional osteosarcomas, the cases considered to be chemotherapysensitive constituted 63% of the cases. The Pgp expression showed no correlationwith the investigated quantitative and semiquantitative parameters(angiogenesis, <italic>P</italic> &#x0003e; .15; proliferation rate, <italic>P</italic> &#x0003e; .54;proliferation index, <italic>P</italic> &#x0003e; .51; p53 expression, <italic>P</italic> &#x0003e; .13; p53index, <italic>P</italic> &#x0003e; .22).</p><p>Six out of 46 osteosarcomas wereassociated with 100%, chemotherapeutically induced tumor necrosis, and in 3 casesthe post-chemotherapy specimens could not be immunohistochemically evaluated. In the former 6 osteosarcomas, the corresponding Pgp expression in thepre-chemotherapy, diagnostic biopsies showed a score of 1 (i.e., chemotherapy sensitivity) in 4 cases, score 2 (chemotherapyresistance) in one case, and for the remaining case the pretreatment biopsycould not be evaluated for technical reasons.</p><p>In the 37 osteosarcomas, wherepost-chemotherapy biopsies were available, there was no statisticallysignificant difference in Pgp expression in the pre- and post-chemotherapybiopsies, respectively (<italic>P</italic> = .10), although the MDR-score changed fromresistance to chemotherapy sensitive status in 4 cases (<xref ref-type="table" rid="tab5">Table 5</xref>). High valuesof the MDR-score in the pre-chemotherapy biopsies were positively correlatedwith high values of the same parameter in the paired, post-chemotherapy tumorspecimens (<italic>P</italic> = .003). Moreover, the expression of Pgp in the primary,diagnostic biopsies was not predictive of the degree of chemotherapy-induced tumor cell necrosis (<italic>P</italic> = .53;<xref ref-type="table" rid="tab6">Table 6</xref>).</p></sec><sec id="subsec5.4"><title>5.4. Prognostic evaluation</title><p>The overall disease-specificsurvival in the entire series of patient, from inclusion to closure of thestudy period, was 50%, with the group of patients receiving chemotherapyshowing a survival of 54%, and in the cohort of patients prior to the era ofchemotherapy the overall survival was 47%. Regarding recurrence-free survival,the same figures were 48%, 53%, and 45%, respectively. The group of patientswith nonconventional osteosarcomas showed no statistical differences regardingthe quantitative variables investigated, when compared to the whole series ofpatients investigated (.06 &#x0003c; <italic>P</italic> &#x0003c; .20), and accordingly, patients withall morphological tumor types were aggregated into one prognostic analysis. Moreover,separate statistical analysis of patients treated before or after theintroduction of chemotherapy showed no individual differences for theinvestigated quantitative variables. Accordingly, the results of the prognosticevaluation are presented for the whole series of patients.</p><p>Patient sex, tumor site and extent,diagnostic delay, and type of surgical treatment were without prognosticimpact, whereas patient age and histological type of osteosarcoma showedprognostic value regarding survival (<xref ref-type="table" rid="tab7">Table 7</xref>; Figures <xref ref-type="fig" rid="fig4">4(b)</xref>, <xref ref-type="fig" rid="fig4">4(d)</xref>). Thus, high-gradeosteosarcomas and age  &#x0003e; 25 years were associated with poorer survival. Largetumor diameter may carry a tendency to shorter survival, however,nonsignificant (<xref ref-type="table" rid="tab7">Table 7</xref>; <xref ref-type="fig" rid="fig4">Figure 4(c)</xref>). Interestingly, neither the administrationof preoperative chemotherapy nor the histological response to chemotherapy (i.e., the extent of tumor necrosis)provided any prognostic impact (<xref ref-type="table" rid="tab7">Table 7</xref>).</p><p>The data obtained regardingangiogenesis, proliferation rate and index, p53 expression and index, and Pgpexpression (<xref ref-type="table" rid="tab8">Table 8</xref> and <xref ref-type="fig" rid="fig4">Figure 4(a)</xref>) were without any prognostic value, neitherregarding patient survival (<italic>P</italic> &#x0003e; .12) nor recurrence of osteosarcoma (<italic>P</italic> &#x0003e; .11).</p></sec></sec><sec sec-type="section" id="sec6"><title>6. DISCUSSION</title><p>Among the traditionalclinicopathological variables, only the type of osteosarcoma and patient age showedprognostic impact regarding survival which is in agreement with other studiesof patients with conventional high-grade sarcomas [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>], but incontrast to earlier investigations. The size [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>] of the tumor,patient sex [<xref ref-type="bibr" rid="B7">7</xref>], and diagnosticdelay [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B7">7</xref>] were nonsignificant regarding prognostic power. In thisstudy, older age, surgical treatment by amputation, no surgical treatment andconventional high-grade osteosarcoma were indicative of an unfavorableprognosis. This may be a reflection of the characteristics of the database inthat the patients have been collected over a period of about 30 years. Moreover, the group of nonconventional osteosarcomas also contained tumors oflower-grade malignancy.</p><p>On the other hand, it is surprisingthat neither preoperative chemotherapy nor histologic response to thattreatment showed prognostic impact. These results disagree with most largestudies of patients treated by preoperative chemotherapy for osteosarcoma [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>],except for a recent randomized phase III study by the <italic>European Osteosarcoma Intergroup</italic> [<xref ref-type="bibr" rid="B19">19</xref>]. The lattermulticenter investigation could not document any relationship between thedegree of histologic response to chemotherapy and patient outcome regardingsurvival [<xref ref-type="bibr" rid="B19">19</xref>]. The results of our study may reflect matters ofsecularity related to the database investigated in that the rarity ofosteosarcoma necessitate collecting patients for study over decades,a time frame within which minor or even majorchanges in treatment may occur. An overall, disease-specific patient survivalof 47% before the introduction of preoperative chemotherapy is rather high,when compared to earlier studies [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>], and considering the very longfollow-up presented in the present study. With such a high survival rate beforethe introduction of preoperative chemotherapy, the true value of the treatmentmay not penetrate from the statistical analysis. One has, however, to considerthe retrospective design of the present study, which also implies possible biasdue to patient selection and data confounding, especially related to treatmentvariables. Nevertheless, the benefit of chemotherapy was reflected by the shiftfrom domination of amputation to preferential limb-sparing and wide surgical resectionbefore and after the introduction of chemotherapy, respectively.</p><p>The fraction of proliferating tumorcells in the investigated series of osteosarcomas ranged from 5% through 90%. This represents a larger range than that obtained in some studies [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B26">26</xref>],but corresponds to the figures reported by German investigators [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>]. We used the TSA technique to improve the often rather weak immunohistologicalstaining for MIB-1, which may explain our higher range of osteosarcoma cells inproliferation cycle. The discrepancies may, however, also be caused by a largenumber of confounding parameters, associated with the differentimmunohistological techniques and antigen retrieval methods, and dealing withretrospective, paraffin-embedded archival tissue, that is, the standardization of fixation methods isquestionable. Furthermore, it has been shown that the Ki-67/MIB-1 antibody maystain noncycling cells that overexpress p53 [<xref ref-type="bibr" rid="B29">29</xref>], which may indeed bethe case in osteosarcomas [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>There was no significant reductionin the proliferation rate in post-chemotherapy specimens, but a statisticallysignificant decrease in the proliferation index was demonstrated. This is,however, just a reflection of the used arithmetic, in that the proliferationindex is related to the area of tissue investigated, and not the number ofMIB-1 negative cells, and the area without tumor cells increases whenchemotherapy makes its effect.</p><p>It has been suggested that MIB-1could be used as an adjuvant variable in the morphological classification ofprimary bone tumors because low-grade osteosarcomas have been shown to have alower proliferation rate than conventional high-grade sarcomas [<xref ref-type="bibr" rid="B24">24</xref>],and low-grade osteosarcomas have a higher MIB-1 rate than fibrous dysplasia [<xref ref-type="bibr" rid="B30">30</xref>]. With the problems associated with immunohistochemical techniques, mentionedabove, and our finding of nonsignificant, lower values of MIB-1 rate innonconventional osteosarcomas, we would advise against employing MIB-1estimates for guidance in classification of osteosarcomas.</p><p>An increased rate of proliferationin metastases, when compared with the MIB-1 rate in the corresponding primaryosteosarcomas, has been published [<xref ref-type="bibr" rid="B31">31</xref>], and thus adds evidence to thesuggested role of MIB-1 rate to act as an indicator of biological behavior ofosteosarcomas [<xref ref-type="bibr" rid="B25">25</xref>]. Prognostic impact of the proliferation rate hasbeen reported in patients with both skeletal [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>] and extraskeletal [<xref ref-type="bibr" rid="B34">34</xref>] osteosarcomas, in contrast to our findings, which, however, are corroborated byother investigators [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B26">26</xref>].</p><p>Most studies addressing theimmunohistochemical expression of p53 in osteosarcomas have used asemiquantitative scoring approach of the staining results [<xref ref-type="bibr" rid="B35">35</xref>&#x02013;<xref ref-type="bibr" rid="B40">40</xref>],often with a 10% or 20% threshold for scoring a tumor as p53 positive. Usingthis approach, the immunoreactivity for p53 has been used in attempts toclassify bone tumors [<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. We have used a strictly quantitative,morphometric technique, in accordance with an earlier editorial on this issue [<xref ref-type="bibr" rid="B42">42</xref>],which explains a frequency of 100% of p53 positivity in our series ofosteosarcomas. The staining pattern, and thus the difference in p53 reactivity,was highly different among individual tumors, showing a range from 5% through100% p53-positive tumor cells. Our reservations in interpreting theimmunohistochemical results for MIB-1 are, however, also valid for p53. Inaddition, we experienced a rather dramatic heterogeneity in p53 staining withinthe same slide from one tumor, and will accordingly recommend arandom-systematic sampling approach in immunohistochemical studies of immunohistochemicalcellular p53-expression.</p><p>In accordance with our results,immunohistochemical investigations of p53 in patients with osteosarcomas havenot demonstrated prognostic impact [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. Changed p53 proteinexpression may not convey mutation in the <italic>P53</italic> gene [<xref ref-type="bibr" rid="B36">36</xref>], and accordingly, genetic studies of <italic>P53</italic> gene alteration may be of value. However, a few studies basedon molecular technology in evaluating the <italic>P53</italic> gene in osteosarcomas have not been able to document prognostic value inosteosarcomas [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>]. Nevertheless, it may, from the theoreticalpoint of view, still be valuable to study various suppressor genes like <italic>P53</italic> and their protein expressions, inthat osteosarcomas are known to occur with higher frequency in persons with impairedor defect suppressor genes like in the case of inherited retinoblastoma [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>]. Indeed, a recent study has shown prognostic impact of the combined informationregarding protein expression of markers of apoptotic cell death, such as p53,bax, and bcl-2, as compared to missing prognostic value displayed by each ofthese molecules individually [<xref ref-type="bibr" rid="B48">48</xref>]. Also, the combination of p53 withinformation regarding Pgp has been documented to contain stronger prognosticinformation than the two variables separately [<xref ref-type="bibr" rid="B49">49</xref>]. Thus, the trueprognostic value of p53/ <italic>P53</italic> on eitherthe protein or gene expression level, respectively, awaits furtherclarification.</p><p>The rate of Pgp positiveosteosarcomas in the present investigation was comparable to findings in otherstudies [<xref ref-type="bibr" rid="B50">50</xref>&#x02013;<xref ref-type="bibr" rid="B52">52</xref>], but on the average, often a little higher thanreported by other investigators [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>]. Again, these discrepanciescan be caused by differing techniques employed, and may not reflect differencesrelated per se to the patient populations studied. Missingcorrelations between Pgp expression and the level of proliferation and p53expression are in agreement with earlier findings [<xref ref-type="bibr" rid="B55">55</xref>].</p><p>Although showing a tightcorrelation, the Pgp expression was not different in primary, diagnosticbiopsies and post-chemotherapy specimens in the present series of patients withosteosarcomas, and the Pgp level in the primary biopsy could not predict theextent of chemotherapy-induced necrosis. The latter findings have been reportedby other investigators [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>], and a meta-analysis including 631patients has confirmed the missing predictive power of Pgp expression withregard to the extent of chemotherapy-induced tumor necrosis [<xref ref-type="bibr" rid="B56">56</xref>]. Ourmethodological approach cannot, however, provide reliable answers to whetherPgp expression is an accurate measure to predict chemotherapy resistance, inthat tumor cell necrosis in itself may not be an accurate measure for thisresistance.</p><p>The incidence of Pgp overexpressionhas been shown to increase after chemotherapy [<xref ref-type="bibr" rid="B52">52</xref>], but our findingscannot be compared reliably with this study, in that the two investigations usequite different scoring schemes for evaluating the MDR-status. Although theincidence of Pgp expression has been shown to be increased in metastatic ascompared to the corresponding primary osteosarcomas [<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>], this doesprobably not imply the development of a more aggressive phenotype [<xref ref-type="bibr" rid="B57">57</xref>],and experimental data suggest that MDR is not upregulated in the course oftumor progression [<xref ref-type="bibr" rid="B58">58</xref>].</p><p>The prognostic impact of MDR/Pgpexpression in osteosarcomas is highly debatable. Some studies have shown Pgpoverexpression in primary, diagnostics biopsies to be predictive of poorprognosis [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B59">59</xref>], which may be of relevance in planning thechemotherapy [<xref ref-type="bibr" rid="B60">60</xref>]. Other authors have not been able to detectprognostic value of the Pgp expression, as determined by immunohistochemistry [<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B61">61</xref>]. Some of the confusion may be related to differences in documenting and scoringimmunohistochemical Pgp expression. We have employed the internationalrecommendation of using cocktails of two or more vendor-standardized anti-Pgpantibody reagents that recognize different epitopes [<xref ref-type="bibr" rid="B20">20</xref>]. This mayimprove the reliability of the immunohistochemical, overall detection of Pgp,but the maybe unique clinical or prognostic impact of the individual antibodyclones used remainsundetected by our approach.</p><p>The immunohistochemicaloverexpression of Pgp may not, however, reflect true genetic amplification ofthe MDR-gene [<xref ref-type="bibr" rid="B62">62</xref>], and quantitative RT-PCR analysis of osteosarcomasfrom 123 patients was unable to demonstrate any relationship between thegenetic MDR expression and prognosis [<xref ref-type="bibr" rid="B63">63</xref>]. So far it seems that mostinvestigations, using immunohistochemical study design, favor prognosticsignificance of Pgp overexpression, which also is the conclusion of themeta-analyses mentioned above [<xref ref-type="bibr" rid="B56">56</xref>].</p><p>Investigations of angiogenesis in humanosteosarcomas are rather sparse, but some studies have shown prognostic impactof estimates of angiogenesis, either directly [<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>] or indirectly [<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>],whereas others have not been able to prove any prognostic value by angioenesis [<xref ref-type="bibr" rid="B18">18</xref>]. Some research based on animal models suggests, however, a role for angiogenesisin the evaluation of progression of osteosarcoma [<xref ref-type="bibr" rid="B66">66</xref>], or in thetreatment of such tumors with antiangiogenetic drugs [<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>]. We couldnot demonstrate any prognostic impact by angiogenesis, and were unable to findany significant differences in the degree of vascularity in pre- andpost-chemotherapy tumor specimens. Moreover, there seems to be no obvious relationshipbetween the grade of angiogenesis and the expression of Pgp in individual osteosarcomas,pointing to the conclusion that angiogenesis is not associated with the accessibilityof chemotherapeutics to the vascular bed of the tumor cells. Only anonsignificant tendency to lower estimates of angiogenesis in nonconventionalosteosarcomas was revealed.</p><p>We have used the Chalkley technique [<xref ref-type="bibr" rid="B22">22</xref>], asrecommended by Vermeulen et al. [<xref ref-type="bibr" rid="B23">23</xref>],whereas other studies [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B64">64</xref>] on human osteosarcomas haveused the microvessel density score for estimating the grade of vascularity withintumors investigated. Although estimates of angiogenesis obtained by these twodifferent approaches may be correlated, a direct comparison is not possible. The sampling approach for both techniques is based on estimation within preselected <italic>hot spots.</italic> Dealing with the highlyheterogeneous vascular morphology in osteosarcomas, this sampling method seemsrational. Optimal sampling schemes, like random systematic sampling, as usedfor scoring of proliferative activity and p53-expression, seemed in our handsunsuited for angiogenesis estimation. Necrosis, condroblastic, and bony-differentiatedareas within the often small diagnostic biopsies from osteosarcomas, as relatedto the focality of neovascularisation (see <xref ref-type="fig" rid="fig2">Figure 2(a)</xref>), made suchstereological approach for estimating architectural structures like vessels futile,in contrast to the suitability of this methodology in quantifying cellularevents like p53-expression and proliferation.</p><p>Furthermore, in our investigation,we have experienced great difficulties in the immunohistological staining byantibodies to CD34, reducing the number of cases available for statisticalanalysis regarding patient survival and recurrence of osteosarcoma. In ourpreliminary investigations, we also tested out the usability of CD31 forimmunohistochemical detection of neoangiogenesis. However, CD31 showed animmense, nonspecific background staining in the decalcified tissue sections,making it impossible to obtain reliably quantitative estimates of angiogenesis.</p><p>Also, the end points for various analyses regardingprognostic impact of angiogenesis are varying, in that some studies focus onsurvival and recurrences, whereas others primarily are addressing the responseto preoperative chemotherapy, anotherpoint disabling bona fide comparisonsbetween various investigations. Moreover, the number of cases in the studies,published so far, is rather sparse. Adding together all these problemsassociated with estimation of neovascularity in osteosarcomas, we believe it istoo early to dismiss angiogenesis as a possible parameter for prognosticevaluation, and for purposes of planning treatment in the eventantiangiogenetic drugs are introduced in treatment trials of patients withosteosarcomas.</p><p>In searching for new morphologic andmolecular predictors of prognosis and treatment outcome, the oncopathologist isfaced with the fight against tumor heterogeneity [<xref ref-type="bibr" rid="B69">69</xref>]. Indeed, this battleseems insurmountable if one considers the sparseness of the primary, diagnosticbiopsy from the mostly bulky osteosarcomas. The intratumoral heterogeneity maybe attributed to intrinsic, tumor cell-specific characteristics or caused bythe environment of the tumor growth. Moreover, the tissue sampling within thetumors and the technical approach used makes heterogeneity one of the mostdifficult obstacles to manage in both a scientific and clinical contexts, even in thecase of monomorphic, small cell malignancies like, for example, Ewing sarcoma [<xref ref-type="bibr" rid="B70">70</xref>]. The diagnostic biopsy from anosteosarcoma will always represent a keyhole of the neoplastic reality. Dealingwith cellular events like p53 expression and proliferative activity, systematicrandom sampling can combat some of the problems related to heterogeneity. Angiogenesis is more difficult in this regard, and a semiquantitative approachseems most feasible for quantifying such architectural aspects. Monitoring theexpression of MDR/Pgp is also highly sensitive to tumor heterogeneity, but onemolecular study, aimed at this particular issue, has revealed very little variationof intratumoral MDR expression [<xref ref-type="bibr" rid="B71">71</xref>]. The overall impact of all theseproblems suggests humbleness in interpreting, and in taking clinicalconsequence of studies of prognostic variables in all kinds of human neoplasms.</p></sec><sec sec-type="section" id="sec7"><title>7. CONCLUSION</title><p>This retrospective, immunohistochemical studyof patients treated for osteosarcoma does not disclose prognostic impact ofquantitative estimates regarding angiogenesis, tumor cell proliferation, p53status, or P-glycoprotein expression. Likewise, the use of preoperativechemotherapy and the extent of induced tumor cell necrosis were withoutprognostic value. Although the study has a retrospective design which mayinflict data confounding and bias, these findings may be associated to the factthat the overall survival was around 50% even before the introduction ofpreoperative chemotherapy. Conflicting evidence in the literature regarding thetrue, prognostic impact of the dogmatized, predictive value of thehistopathologic response to preoperative chemotherapy in patients sufferingfrom osteosarcoma may ask for intensified research regarding the pretreatment,predictive value of, for example, patient-specific qualities like MDR status.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors wish to thank the laboratorytechnicians at the University Institute of Pathology, for skillful assistance withtissue processing. They are grateful to Professor O. Myhre Jensen for hiscontribution to the collection of the studied osteosarcomas, to collaboratorsat the Sarcoma Center of Aarhus University Hospital, and other Departments ofPathology within Denmark, andto Dr. Massimo Serra, Laboratorio di Ricerca Oncologica, Istituti OrtopediciRizzoli, Bologna, Italy for providing valuableguidance in optimizing immunohistochemical techniques. A special thank to OleSteen Nielsen for providing access to the analyzed clinical data. This studywas supported by grants from Lily Benthine Lund'sFoundation, Hans and Nora Buchard's Foundation, Anna and Jacob Jacobsen'sGrant, Edith and Olfert Dines Hansen's Grant, Max and Inger Woerzner's Grant,The Foundation for the Advance of Medical Science, Frits, Georg and MarieCecilie Glud's Grant, Helga and Peter Korning's Foundation, the ScienceFoundation of the Danish Medical Association, Eva and Henry Fraenkel's Foundation,Inge and Joergen Larsen's Grant, P. A. Messerschmidt and Spouse's Foundation, The Science Initiative of Aarhus County,The Science Foundation of Aarhus Sygehus, The Science Foundation of AarhusUniversity, King Christian X's Foundation, Werner Richter and Spouse'sFoundation, The Foundation of 17th December 1981, Sven and Ina Hansen'sFoundation, Karhrine and Vigo Skovgaard's Foundation, Karen A. Tolstrup'sFoundation, Jacob Madsens ans spouse Olga Madsen's Foundation, HoerslevFoundation, Karen Elise Jensen's Foundation, Svend Faelding's Foundation,Sigvald and Edith Rasmussen's Foundation, Raimond and Dagmar Ringgaard-Bohn'sFoundation, Else and Mogens Wedell-Wedellsborg's Foundation, The BeckettFoundation, Dagmar Marshall's Foundation, Svend Helge Arvid Schroeder andspouse Ketty Lydia Larsen Schroeder's Foundation, the clinical Research Unit atAarhus University Hospital of the Danish Cancer Society, and A. P. Moeller'sFoundation.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentzen</surname><given-names>SM</given-names></name><name><surname>Poulsen</surname><given-names>HS</given-names></name><name><surname>Kaae</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prognostic factors in osteosarcomas. A regression analysis</article-title><source><italic>Cancer</italic></source><year>1988</year><volume>62</volume><issue>1</issue><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">3164231</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>WF</given-names></name><name><surname>Ivins</surname><given-names>JC</given-names></name><name><surname>Unni</surname><given-names>KK</given-names></name><name><surname>Beabout</surname><given-names>JW</given-names></name><name><surname>Golenzer</surname><given-names>HJ</given-names></name><name><surname>Black</surname><given-names>LE</given-names></name></person-group><article-title>Prognostic variables in osteosarcoma: a multi-institutional study</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1989</year><volume>81</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">2642303</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glasser</surname><given-names>DB</given-names></name><name><surname>Lane</surname><given-names>JM</given-names></name><name><surname>Huvos</surname><given-names>AG</given-names></name><name><surname>Marcove</surname><given-names>RC</given-names></name><name><surname>Rosen</surname><given-names>G</given-names></name></person-group><article-title>Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience</article-title><source><italic>Cancer</italic></source><year>1992</year><volume>69</volume><issue>3</issue><fpage>698</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">1730120</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bieling</surname><given-names>P</given-names></name><name><surname>Rehan</surname><given-names>N</given-names></name><name><surname>Winkler</surname><given-names>P</given-names></name><etal/></person-group><article-title>Tumor size and prognosis in aggressively treated osteosarcoma</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1996</year><volume>14</volume><issue>3</issue><fpage>848</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">8622033</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Bertoni</surname><given-names>F</given-names></name><name><surname>Mercuri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute</article-title><source><italic>Annals of Oncology</italic></source><year>2001</year><volume>12</volume><issue>8</issue><fpage>1145</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">11583198</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>AM</given-names></name><name><surname>Bell</surname><given-names>RS</given-names></name><name><surname>Goodwin</surname><given-names>PJ</given-names></name></person-group><article-title>Prognostic factors in osteosarcoma: a critical review</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1994</year><volume>12</volume><issue>2</issue><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">8113851</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Kempf-Bielack</surname><given-names>B</given-names></name><name><surname>Delling</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2002</year><volume>20</volume><issue>3</issue><fpage>776</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">11821461</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salzer-Kunstschik</surname><given-names>M</given-names></name><name><surname>Brand</surname><given-names>G</given-names></name><name><surname>Delling</surname><given-names>G</given-names></name></person-group><article-title>Bestimmung des morphologischen regressionsgrades nach chemotherapie bei malignen knochentumoren</article-title><source><italic>Pathologe</italic></source><year>1983</year><volume>4</volume><issue>3</issue><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">6576329</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Picci</surname><given-names>P</given-names></name><name><surname>Bacci</surname><given-names>G</given-names></name><name><surname>Campanacci</surname><given-names>M</given-names></name><etal/></person-group><article-title>Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor</article-title><source><italic>Cancer</italic></source><year>1985</year><volume>56</volume><issue>7</issue><fpage>1515</fpage><lpage>1521</lpage><pub-id pub-id-type="pmid">3861228</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jong</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name><name><surname>Mendes</surname><given-names>MG</given-names></name><name><surname>Wunder</surname><given-names>JS</given-names></name><name><surname>Bell</surname><given-names>RS</given-names></name><name><surname>Kandel</surname><given-names>R</given-names></name></person-group><article-title>Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases</article-title><source><italic>Sarcoma</italic></source><year>2000</year><volume>4</volume><issue>1-2</issue><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">18521434</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gokgoz</surname><given-names>N</given-names></name><name><surname>Wunder</surname><given-names>JS</given-names></name><name><surname>Mousses</surname><given-names>S</given-names></name><name><surname>Eskandarian</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>RS</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name></person-group><article-title>Comparison of <italic>p53</italic> mutations in patients with localized osteosarcoma and metastatic osteosarcoma</article-title><source><italic>Cancer</italic></source><year>2001</year><volume>92</volume><issue>8</issue><fpage>2181</fpage><lpage>2189</lpage><pub-id pub-id-type="pmid">11596036</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldini</surname><given-names>N</given-names></name><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Barbanti-Br&#x000f2;dano</surname><given-names>G</given-names></name><etal/></person-group><article-title>Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1995</year><volume>333</volume><issue>21</issue><fpage>1380</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">7477118</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>IJ</given-names></name><name><surname>Nooij</surname><given-names>MA</given-names></name><name><surname>Whelan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2007</year><volume>99</volume><issue>2</issue><fpage>112</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">17227995</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantadakis</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Reisch</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma</article-title><source><italic>Journal of Pediatric Hematology Oncology</italic></source><year>2001</year><volume>23</volume><issue>5</issue><fpage>286</fpage><lpage>289</lpage></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name></person-group><article-title xml:lang="ZH">Correlation of tumor microvesseldensity with prognosis in osteogenic sarcoma</article-title><source><italic>Zhonghua Bing Li Xue Za Zhi</italic></source><year>1997</year><volume>26</volume><issue>5</issue><fpage>266</fpage><lpage>269</lpage><comment>(Chinese).</comment><pub-id pub-id-type="pmid">10374332</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mikuli&#x00107;</surname><given-names>D</given-names></name><name><surname>Ili&#x00107;</surname><given-names>I</given-names></name><name><surname>&#x00106;epuli&#x00107;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor angiogenesis and outcome in osteosarcoma</article-title><source><italic>Pediatric Hematology and Oncology</italic></source><year>2004</year><volume>21</volume><issue>7</issue><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">15626017</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kreuter</surname><given-names>M</given-names></name><name><surname>Bieker</surname><given-names>R</given-names></name><name><surname>Bielaek</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Prognostic relevance of increased angiogenesis in osteosarcoma</article-title><source><italic>Clinical Cancer Research</italic></source><year>2004</year><volume>10</volume><issue>24</issue><fpage>8531</fpage><lpage>8537</lpage><pub-id pub-id-type="pmid">15623635</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ek</surname><given-names>ET</given-names></name><name><surname>Ojaimi</surname><given-names>J</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name><name><surname>Choong</surname><given-names>PF</given-names></name></person-group><article-title>Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?</article-title><source><italic>Oncology Reports</italic></source><year>2006</year><volume>16</volume><issue>1</issue><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16786118</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edmonson</surname><given-names>JH</given-names></name><name><surname>Long</surname><given-names>HJ</given-names></name><name><surname>Richardson</surname><given-names>RL</given-names></name><name><surname>Creagan</surname><given-names>ET</given-names></name><name><surname>Green</surname><given-names>SJ</given-names></name></person-group><article-title>Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas</article-title><source><italic>Cancer Chemotherapy and Pharmacology</italic></source><year>1985</year><volume>15</volume><issue>2</issue><fpage>181</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">2990751</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>WT</given-names></name><name><surname>Grogan</surname><given-names>TM</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations</article-title><source><italic>Cancer Research</italic></source><year>1996</year><volume>56</volume><issue>13</issue><fpage>3010</fpage><lpage>3020</lpage><pub-id pub-id-type="pmid">8674056</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gundersen</surname><given-names>HJG</given-names></name></person-group><article-title>Notes on the estimation of the numerical density of arbitrary profiles: the edge effect</article-title><source><italic>Journal of Microscopy</italic></source><year>1977</year><volume>111</volume><fpage>219</fpage><lpage>233</lpage></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chalkley</surname><given-names>HW</given-names></name></person-group><article-title>Method for the quantitative morphologic analysis of tissues</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1943</year><volume>4</volume><fpage>47</fpage><lpage>53</lpage></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>PB</given-names></name><name><surname>Gasparini</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Colpaert</surname><given-names>C</given-names></name></person-group><article-title>Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours</article-title><source><italic>European Journal of Cancer</italic></source><year>2002</year><volume>38</volume><issue>12</issue><fpage>1564</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">12142044</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>E</given-names></name><name><surname>Roessner</surname><given-names>A</given-names></name><name><surname>Gerdes</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improved grading of bone tumors with the monoclonal antibody Ki-67</article-title><source><italic>Journal of Cancer Research and Clinical Oncology</italic></source><year>1986</year><volume>112</volume><issue>3</issue><fpage>281</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">3536945</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>E</given-names></name><name><surname>Roessner</surname><given-names>A</given-names></name><name><surname>Wuisman</surname><given-names>P</given-names></name><name><surname>H&#x000e4;rle</surname><given-names>A</given-names></name><name><surname>Grundmann</surname><given-names>E</given-names></name></person-group><article-title>The proliferation behavior of bone tumors investigated with the monoclonal antibody Ki-67</article-title><source><italic>Current Topics in Pathology</italic></source><year>1989</year><volume>80</volume><fpage>91</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">2776497</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H-R</given-names></name><name><surname>Park</surname><given-names>Y-K</given-names></name></person-group><article-title>Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone</article-title><source><italic>Journal of Korean Medical Science</italic></source><year>1995</year><volume>10</volume><issue>5</issue><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">8750062</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x000f6;sl</surname><given-names>M</given-names></name><name><surname>Amling</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><etal/></person-group><article-title>Osteosarkom&#x02014;apoptose und proliferation untersuchung zur bcl-2-expression</article-title><source><italic>Der Pathologe</italic></source><year>1994</year><volume>15</volume><issue>6</issue><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">7855102</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stenzel</surname><given-names>I</given-names></name><name><surname>P&#x000f6;sl</surname><given-names>M</given-names></name><name><surname>Ritzel</surname><given-names>H</given-names></name><name><surname>Hentz</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><name><surname>Delling</surname><given-names>G</given-names></name></person-group><article-title>Zellproliferation bei knochentumoren immunhistologische untersuchung zur Ki-67-proteinexpression</article-title><source><italic>Der Pathologe</italic></source><year>1996</year><volume>17</volume><issue>1</issue><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">8685097</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Oijen</surname><given-names>MGCT</given-names></name><name><surname>Medema</surname><given-names>RH</given-names></name><name><surname>Slootweg</surname><given-names>PJ</given-names></name><name><surname>Rijksen</surname><given-names>G</given-names></name></person-group><article-title>Positivity of the proliferation marker Ki-67 in noncycling cells</article-title><source><italic>American Journal of Clinical Pathology</italic></source><year>1998</year><volume>110</volume><issue>1</issue><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9661919</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>J</given-names></name><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Kakizaki</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>A</given-names></name><name><surname>Hotta</surname><given-names>T</given-names></name></person-group><article-title>Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis</article-title><source><italic>Human Pathology</italic></source><year>2000</year><volume>31</volume><issue>6</issue><fpage>633</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">10872654</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Naka</surname><given-names>T</given-names></name><name><surname>Takeshita</surname><given-names>M</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Tsuneyoshi</surname><given-names>M</given-names></name></person-group><article-title>Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study</article-title><source><italic>Human Pathology</italic></source><year>2000</year><volume>31</volume><issue>6</issue><fpage>709</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">10872665</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Manara</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Clinical relevance of Ki-67 expression in bone tumors</article-title><source><italic>Cancer</italic></source><year>1995</year><volume>75</volume><issue>3</issue><fpage>806</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">7828130</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez-Rodr&#x000ed;guez</surname><given-names>NA</given-names></name><name><surname>Correa</surname><given-names>E</given-names></name><name><surname>Sotelo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma</article-title><source><italic>Cancer Detection and Prevention</italic></source><year>2001</year><volume>25</volume><issue>2</issue><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">11341357</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>ML</given-names></name><name><surname>Schumacher</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>OM</given-names></name><name><surname>Nielsen</surname><given-names>OS</given-names></name><name><surname>Keller</surname><given-names>J</given-names></name></person-group><article-title>Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases</article-title><source><italic>American Journal of Surgical Pathology</italic></source><year>1998</year><volume>22</volume><issue>5</issue><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">9591729</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefanou</surname><given-names>DG</given-names></name><name><surname>Nonni</surname><given-names>AV</given-names></name><name><surname>Agnantis</surname><given-names>NJ</given-names></name><name><surname>Athanassiadou</surname><given-names>SE</given-names></name><name><surname>Briassoulis</surname><given-names>E</given-names></name><name><surname>Pavlidis</surname><given-names>N</given-names></name></person-group><article-title>p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study</article-title><source><italic>Anticancer Research</italic></source><year>1998</year><volume>18</volume><issue>6B</issue><fpage>4673</fpage><lpage>4681</lpage><pub-id pub-id-type="pmid">9891539</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wadayama</surname><given-names>B</given-names></name><name><surname>Toguchida</surname><given-names>J</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>MS</given-names></name><name><surname>Kotoura</surname><given-names>Y</given-names></name><name><surname>Yamamuro</surname><given-names>T</given-names></name></person-group><article-title>p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas</article-title><source><italic>British Journal of Cancer</italic></source><year>1993</year><volume>68</volume><issue>6</issue><fpage>1134</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">8260365</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Wehrmann</surname><given-names>B</given-names></name><name><surname>Radig</surname><given-names>K</given-names></name><etal/></person-group><article-title>Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression</article-title><source><italic>General &#x00026; Diagnostic Pathology</italic></source><year>1995</year><volume>141</volume><issue>2</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">8548600</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lonardo</surname><given-names>F</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Huvos</surname><given-names>AG</given-names></name><name><surname>Healey</surname><given-names>J</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name></person-group><article-title>p53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate</article-title><source><italic>Cancer</italic></source><year>1997</year><volume>79</volume><issue>8</issue><fpage>1541</fpage><lpage>1547</lpage><pub-id pub-id-type="pmid">9118036</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Dockhorn-Dwornizak</surname><given-names>B</given-names></name><name><surname>Blasius</surname><given-names>S</given-names></name><etal/></person-group><article-title>Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone</article-title><source><italic>Journal of Cancer Research and Clinical Oncology</italic></source><year>1993</year><volume>119</volume><issue>3</issue><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">8418091</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorlick</surname><given-names>R</given-names></name><name><surname>Huvos</surname><given-names>AG</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><etal/></person-group><article-title>Expression of HER2/<italic>erb</italic>B-2 correlates with survival in osteosarcoma</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1999</year><volume>17</volume><issue>9</issue><fpage>2781</fpage><lpage>2788</lpage><pub-id pub-id-type="pmid">10561353</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naka</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Shinohara</surname><given-names>N</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Sugioka</surname><given-names>Y</given-names></name><name><surname>Tsuneyoshi</surname><given-names>M</given-names></name></person-group><article-title>Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma</article-title><source><italic>Cancer</italic></source><year>1995</year><volume>76</volume><issue>6</issue><fpage>972</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">8625223</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>PA</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><article-title>p53 In tumour pathology: can we trust immunohistochemistry? - revisited!</article-title><source><italic>The Journal of Pathology</italic></source><year>1994</year><volume>172</volume><issue>1</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7931821</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>A</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas</article-title><source><italic>Japanese Journal of Cancer Research</italic></source><year>1998</year><volume>89</volume><issue>5</issue><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">9685858</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toguchida</surname><given-names>J</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Ritchie</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mutation spectrum of the <italic>p53</italic> gene in bone and soft tissue sarcomas</article-title><source><italic>Cancer Research</italic></source><year>1992</year><volume>52</volume><issue>22</issue><fpage>6194</fpage><lpage>6199</lpage><pub-id pub-id-type="pmid">1423262</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radig</surname><given-names>K</given-names></name><name><surname>Schneider-Stock</surname><given-names>R</given-names></name><name><surname>Haeckel</surname><given-names>C</given-names></name><name><surname>Neumann</surname><given-names>W</given-names></name><name><surname>Roessner</surname><given-names>A</given-names></name></person-group><article-title>						<italic>p53</italic> gene mutations in osteosarcomas of low-grade malignancy</article-title><source><italic>Human Pathology</italic></source><year>1998</year><volume>29</volume><issue>11</issue><fpage>1310</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">9824113</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walkley</surname><given-names>CR</given-names></name><name><surname>Qudsi</surname><given-names>R</given-names></name><name><surname>Sankaran</surname><given-names>VG</given-names></name><etal/></person-group><article-title>Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease</article-title><source><italic>Genes &#x00026; Development</italic></source><year>2008</year><volume>22</volume><issue>12</issue><fpage>1662</fpage><lpage>1676</lpage><pub-id pub-id-type="pmid">18559481</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CW</given-names></name><name><surname>Aslo</surname><given-names>A</given-names></name><name><surname>Won</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Lampkin</surname><given-names>B</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><article-title>Alterations of the <italic>p53, Rb</italic> and <italic>MDM2</italic> genes in osteosarcoma</article-title><source><italic>Journal of Cancer Research and Clinical Oncology</italic></source><year>1996</year><volume>122</volume><issue>9</issue><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">8781571</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaseta</surname><given-names>M-KA</given-names></name><name><surname>Khaldi</surname><given-names>L</given-names></name><name><surname>Gomatos</surname><given-names>IP</given-names></name><etal/></person-group><article-title>Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma</article-title><source><italic>Journal of Surgical Oncology</italic></source><year>2008</year><volume>97</volume><issue>3</issue><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">18161867</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YB</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Oh</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group><article-title>The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma</article-title><source><italic>International Orthopaedics</italic></source><year>2001</year><volume>24</volume><issue>6</issue><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">11294418</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>HSL</given-names></name><name><surname>Grogan</surname><given-names>TM</given-names></name><name><surname>Haddad</surname><given-names>G</given-names></name><name><surname>DeBoer</surname><given-names>G</given-names></name><name><surname>Ling</surname><given-names>V</given-names></name></person-group><article-title>P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1997</year><volume>89</volume><issue>22</issue><fpage>1706</fpage><lpage>1715</lpage><pub-id pub-id-type="pmid">9390540</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radig</surname><given-names>K</given-names></name><name><surname>Hackel</surname><given-names>C</given-names></name><name><surname>Herting</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype</article-title><source><italic>General &#x00026; Diagnostic Pathology</italic></source><year>1997</year><volume>142</volume><issue>3-4</issue><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">9065577</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x000f6;sl</surname><given-names>M</given-names></name><name><surname>Amling</surname><given-names>M</given-names></name><name><surname>Grahl</surname><given-names>K</given-names></name><etal/></person-group><article-title>P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An Immunohistochemical study</article-title><source><italic>General &#x00026; Diagnostic Pathology</italic></source><year>1997</year><volume>142</volume><issue>5-6</issue><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">9228255</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Manara</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Analysis of P-glycoprotein expression in osteosarcoma</article-title><source><italic>European Journal of Cancer</italic></source><year>1995</year><volume>31</volume><issue>12</issue><fpage>1998</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">8562155</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Bertoni</surname><given-names>F</given-names></name><name><surname>Zanella</surname><given-names>L</given-names></name><etal/></person-group><article-title>Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>100</volume><issue>9</issue><fpage>1936</fpage><lpage>1942</lpage><pub-id pub-id-type="pmid">15112275</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kakar</surname><given-names>S</given-names></name><name><surname>Mihalov</surname><given-names>M</given-names></name><name><surname>Chachlani</surname><given-names>NA</given-names></name><name><surname>Ghosh</surname><given-names>L</given-names></name><name><surname>Johnstone</surname><given-names>H</given-names></name></person-group><article-title>Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma</article-title><source><italic>Journal of Surgical Oncology</italic></source><year>2000</year><volume>73</volume><issue>2</issue><fpage>125</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">10694652</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pakos</surname><given-names>EE</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><article-title>The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A <italic>meta-analysis</italic></article-title><source><italic>Cancer</italic></source><year>2003</year><volume>98</volume><issue>3</issue><fpage>581</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">12879476</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Nicoletti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Multidrug resistance and malignancy in human osteosarcoma</article-title><source><italic>Cancer Research</italic></source><year>1996</year><volume>56</volume><issue>10</issue><fpage>2434</fpage><lpage>2439</lpage><pub-id pub-id-type="pmid">8625324</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trammell</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>CB</given-names></name><name><surname>Barker</surname><given-names>JR</given-names></name><name><surname>Bell</surname><given-names>RS</given-names></name><name><surname>Allan</surname><given-names>DG</given-names></name></person-group><article-title>Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model</article-title><source><italic>Journal of Orthopaedic Research</italic></source><year>2000</year><volume>18</volume><issue>3</issue><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">10937633</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hornicek</surname><given-names>FJ</given-names></name><name><surname>Gebhardt</surname><given-names>MC</given-names></name><name><surname>Wolfe</surname><given-names>MW</given-names></name><etal/></person-group><article-title>P-glycoprotein levels predict poor outcome in patients with osteosarcoma</article-title><source><italic>Clinical Orthopaedics &#x00026; Related Research</italic></source><year>2000</year><issue>373</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10810457</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldini</surname><given-names>N</given-names></name><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><etal/></person-group><article-title>P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy</article-title><source><italic>Journal of Orthopaedic Research</italic></source><year>1999</year><volume>17</volume><issue>5</issue><fpage>629</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">10569469</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shnyder</surname><given-names>SD</given-names></name><name><surname>Hayes</surname><given-names>AJ</given-names></name><name><surname>Pringle</surname><given-names>J</given-names></name><name><surname>Archer</surname><given-names>CW</given-names></name></person-group><article-title>P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma</article-title><source><italic>British Journal of Cancer</italic></source><year>1998</year><volume>78</volume><issue>6</issue><fpage>757</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">9743295</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandel</surname><given-names>RA</given-names></name><name><surname>Campbell</surname><given-names>S</given-names></name><name><surname>Noble-Topham</surname><given-names>SE</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name></person-group><article-title>Correlation of P-glycoprotein detection by immunohistochemistry with mdr-l mRNA levels in osteosarcomas. Pilot study</article-title><source><italic>Diagnostic Molecular Pathology</italic></source><year>1995</year><volume>4</volume><issue>1</issue><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7735558</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wunder</surname><given-names>JS</given-names></name><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Aneliunas</surname><given-names>V</given-names></name><etal/></person-group><article-title>MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2000</year><volume>18</volume><issue>14</issue><fpage>2685</fpage><lpage>2694</lpage><pub-id pub-id-type="pmid">10894867</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>M</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Akatsuka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis</article-title><source><italic>Clinical Cancer Research</italic></source><year>2000</year><volume>6</volume><issue>2</issue><fpage>572</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">10690541</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Handa</surname><given-names>A</given-names></name><name><surname>Tokunaga</surname><given-names>T</given-names></name><name><surname>Tsuchida</surname><given-names>T</given-names></name><etal/></person-group><article-title>Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma</article-title><source><italic>International Journal of Oncology</italic></source><year>2000</year><volume>17</volume><issue>2</issue><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">10891538</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coomber</surname><given-names>BL</given-names></name><name><surname>Denton</surname><given-names>J</given-names></name><name><surname>Sylvestre</surname><given-names>A</given-names></name><name><surname>Kruth</surname><given-names>S</given-names></name></person-group><article-title>Blood vessel density in canine osteosarcoma</article-title><source><italic>Canadian Journal of Veterinary Research</italic></source><year>1998</year><volume>62</volume><issue>3</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">9684049</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Kuratsu</surname><given-names>S</given-names></name><name><surname>Hosono</surname><given-names>N</given-names></name><name><surname>Izawa</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>A</given-names></name></person-group><article-title>Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma</article-title><source><italic>International Journal of Cancer</italic></source><year>1995</year><volume>61</volume><issue>1</issue><fpage>148</fpage><lpage>152</lpage></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morishita</surname><given-names>T</given-names></name><name><surname>Mii</surname><given-names>Y</given-names></name><name><surname>Miyauchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy of the angiogenesis inhibitor <italic>O</italic>-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats</article-title><source><italic>Japanese Journal of Clinical Oncology</italic></source><year>1995</year><volume>25</volume><issue>2</issue><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">7745819</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>D</given-names></name></person-group><article-title>New entities, concepts, and questions in childhood tumor pathology</article-title><source><italic>General &#x00026; Diagnostic Pathology</italic></source><year>1995</year><volume>141</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">8542501</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Sullivan</surname><given-names>M</given-names></name><name><surname>Budhraja</surname><given-names>V</given-names></name><name><surname>Sadovsky</surname><given-names>Y</given-names></name><name><surname>Pfeifer</surname><given-names>JD</given-names></name></person-group><article-title>Tumor heterogeneity affects the precision of microarray analysis</article-title><source><italic>Diagnostic Molecular Pathology</italic></source><year>2005</year><volume>14</volume><issue>2</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">15905688</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PD</given-names></name><name><surname>Noble-Topham</surname><given-names>SE</given-names></name><name><surname>Bell</surname><given-names>RS</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name></person-group><article-title>Quantitative analysis of multidrug resistance gene expression in human osteosarcomas</article-title><source><italic>British Journal of Cancer</italic></source><year>1996</year><volume>74</volume><issue>7</issue><fpage>1046</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">8855972</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Field of vision showing anosteosarcoma stained immunohistochemically by MIB-1 to demonstrate cells inproliferation cycle (brown nuclear stain). A counting frame has beensuperimposed onto the histologic section for estimation of the rate and indexof neoplastic proliferation. Using an <italic>unbiased</italic> two-dimensional counting rule, nuclei in focus inside the frame or on thehatched, blue edges are counted, as long as they do not intersect with thefully drawn, red exclusion edges of the frame or their extensions. In thisexample, 6 nuclei in cycle (brown) and 10 &#x0201c;resting&#x0201d; nuclei (blue) are counted (originalmagnification: 400X).</p></caption><graphic xlink:href="SRCM2008-874075.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>(a) Low-power view of a histologic section from anosteosarcoma, showing a microvascular hot spot in the lower left corner (originalmagnification: 40X). (b) Histologic section with the Chalkley graticulesuperimposed. The graticule, equipped with 25 stochastically spaced points, isrotated until the highest number of these 25 points coincides with immunohistochemicallystained microvascular profiles in the tumor tissue. The mean of three hot spotcounts is reported as the angiogenetic Chalkley number (immunohistochemicalstain by CD34 to highlight endothelial cells and vascular profiles; originalmagnification: 200X).</p></caption><graphic xlink:href="SRCM2008-874075.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Histologic section of anosteosarcoma stained by a &#x0201c;cocktail&#x0201d; of antibodies against P-glycoprotein (MDR). In this case, the stain shows intense membranous accentuation with a sparsecytoplasmic reaction (MDR score = 3; original magnification 200X).</p></caption><graphic xlink:href="SRCM2008-874075.003"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Kaplan-Meier plots of survival inpatients with osteosarcoma regarding (a) multiple drug resistance score (<italic>P</italic> = .12; log rank test), (b) histological type of osteosarcoma (<italic>P</italic> = .02),(c) tumor diameter (<italic>P</italic> = .11), (d) and patient age at diagnosis (<italic>P</italic> = .03).</p></caption><graphic xlink:href="SRCM2008-874075.004"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Clinicopathological data of 117 patients with primary osteosarcoma.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">N</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Sex</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Women</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>41</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Men</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>76</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Age</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Mean (years)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>23.8</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>SD (years)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>16.6</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Range (years)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>4&#x02013;74</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Tumor site</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Humerus and radius</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>12</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Pelvis</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>10</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Femur</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>66</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Tibia</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>21</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Fibula</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>6</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Tarsal bones</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>2</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Extent of tumor</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Intraosseous</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>6</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>+ Cortical breakthrough</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>16</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>+ Soft tissue extension</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>95</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Type of osteosarcoma</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Classical high grade</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>98</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Other types</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>19</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Largest tumor diameter</italic><sup>a</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Mean (cm)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>10.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>SD (cm)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>3.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Range (cm)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>3&#x02013;20</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Diagnostic delay</italic><sup>b</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Mean (months)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>5.3</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>SD (months)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>3.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Range (months)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>1&#x02013;36</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Type of surgical treatment</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>None</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>5</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Tumor resection</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>26</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Amputation</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>86</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Histological radicality of surgery</italic><sup>c</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Intralesional resection</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>4</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Marginal resection</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>5</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Wide resection(radical)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>49</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Amputation (radical)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>54</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Chemotherapy</italic><sup>d</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>+ Preoperative chemotherapy</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>46</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x02212;  Preoperative chemotherapy</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>63</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>+ Other kind of chemotherapy</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>8</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Radiation therapy</italic><sup>e</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>+ Radiation therapy</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>7</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x02212;  Radiation therapy</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>110</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Clinical response to primary treatment</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Complete clinical response</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>107</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Persistent disease</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>10</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Histological response to preoperative chemotherapy</italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>100% tumor necrosis</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>6</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x0003e;90% tumor necrosis</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>11</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>50&#x02013;90% tumor necrosis</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>14</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>&#x0003c;50% tumor necrosis</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>10</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>No necrosis</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>5</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Recurrent disease</italic><sup>f</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>No recurrence</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>51</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>+ Recurrence</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>56</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Persistent disease</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>10</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Survival status</italic><sup>g</sup></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Survivors</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>58</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Death caused by OS</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>58</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Death from unrelated disease</td><td align="center" rowspan="1" colspan="1"><italic>&#x02003;</italic>1</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>Tumer diameter not known for 3 patients.</p><p>						<sup>b</sup>Diagnostic delay was estimated from the anamnestic informations given in the clinical records and was unknown for 19 patients.</p><p>						<sup>c</sup>Five patients did not receive surgical treatment, but were by own wish treated by either chemotherapy and/or radiation therapy alone/combined or refused any treatment.</p><p>						<sup>d</sup>One patient received chemotherapy as the only treatment modality and did not wish the subsequent surgery, whereas 7 other patients received chemotherapy as adjuvant to other treatment.</p><p>						<sup>e</sup>Two patients received radiation therapy as the only treatment.</p><p>						<sup>f</sup>Recurrence status at the closure of the study.</p><p>						<sup>g</sup>Survival status at the closure of the study.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Histologicalradicality of surgery in relation to preoperative chemotherapy course<sup>a</sup>. <italic>P</italic><italic> value</italic><sup>b</sup> = .00002.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Type of histological radicality of surgical specimen:</th><th align="center" rowspan="1" colspan="1">Preoperative chemotherapy not given</th><th align="center" rowspan="1" colspan="1">Preoperative chemotherapy given</th><th align="center" rowspan="1" colspan="1">&#x02211;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Intralesional or marginal resection</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Wide resection</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">49</td></tr><tr><td align="left" rowspan="1" colspan="1"> Amputation</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02211;</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">112</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>Five patientsdid not receive surgical treatment, but were by own wish treated by eitherchemotherapy and/or radiation therapy alone/combined or refused any treatment.</p><p>						<sup>b</sup><italic>&#x003c7;</italic><sup>2</sup>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Angiogenesis, tumor cellproliferation, and nuclear p53 expression in primary, diagnostic biopsies fromosteosarcomas.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">Range</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Angiogenesis<sup>a</sup></td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">6.79</td><td align="center" rowspan="1" colspan="1">2.50</td><td align="center" rowspan="1" colspan="1">2.00&#x02013;14.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Proliferation rate (%)</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">50.6</td><td align="center" rowspan="1" colspan="1">18.8</td><td align="center" rowspan="1" colspan="1">5.1&#x02013;90.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Proliferation index (mm<sup>&#x02212;2</sup>)</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">1990</td><td align="center" rowspan="1" colspan="1">1164</td><td align="center" rowspan="1" colspan="1">14&#x02013;8388</td></tr><tr><td align="left" rowspan="1" colspan="1">p53 expression (%)</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">68.0</td><td align="center" rowspan="1" colspan="1">24.4</td><td align="center" rowspan="1" colspan="1">5.5&#x02013;100.0</td></tr><tr><td align="left" rowspan="1" colspan="1">p53 index (mm<sup>&#x02212;2</sup>)</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">2615</td><td align="center" rowspan="1" colspan="1">1437</td><td align="center" rowspan="1" colspan="1">15&#x02013;10556</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>It wastechnically impossible to obtain evaluable immunohistochemical stains for CD34in 12 cases.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>The relationships between estimatesof tumor cell proliferation and nuclear p53 expression in 46 osteosarcomas, beforeand after preoperative chemotherapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Pre-chemotherapy</th><th align="center" colspan="2" rowspan="1">Post-chemotherapy</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1"><italic>P</italic><italic> value</italic><sup>a</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Proliferation rate (%)</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">54.48</td><td align="center" rowspan="1" colspan="1">39<sup>b</sup></td><td align="center" rowspan="1" colspan="1">42.8</td><td align="center" rowspan="1" colspan="1">.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Proliferation index (mm<sup>&#x02212;2</sup>)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">2230</td><td align="center" rowspan="1" colspan="1">39<sup>b</sup></td><td align="center" rowspan="1" colspan="1">1327</td><td align="center" rowspan="1" colspan="1"><bold>.02</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">p53 expression (%)</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">61.0</td><td align="center" rowspan="1" colspan="1">39<sup>b</sup></td><td align="center" rowspan="1" colspan="1">64.8</td><td align="center" rowspan="1" colspan="1">.85</td></tr><tr><td align="left" rowspan="1" colspan="1">p53 index (mm<sup>&#x02212;2</sup>)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">2573</td><td align="center" rowspan="1" colspan="1">39<sup>b</sup></td><td align="center" rowspan="1" colspan="1">2190</td><td align="center" rowspan="1" colspan="1">.32</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>Student's unpaired <italic>t</italic>-test.</p><p>						<sup>b</sup>One case could not be evaluated, whereas 6 cases were associated with 100% tumornecrosis.</p><p>						<sup>c</sup>Index reflects the number of positive nuclear profiles pr. mm<sup>2</sup> tissue.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" position="float"><label>Table 5</label><caption><p>Multipledrug resistance (Pgp expression) in 37 osteosarcomas in pre- andpost-chemotherapy biopsies, respectively<sup>a</sup>. <italic>P</italic><italic> value</italic><sup>c</sup> = .10.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Pre-chemotherapy MDR-score<sup>b</sup></th><th align="center" colspan="2" rowspan="1">Post-chemotherapy MDR-score<sup>b</sup></th><th align="center" rowspan="2" colspan="1">&#x02211;</th></tr><tr><th align="center" rowspan="1" colspan="1">&#x0003c;2</th><th align="center" rowspan="1" colspan="1">&#x02265;2</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x0003c;2</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;2 </td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02211;</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">37</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>Three casescould not be evaluated in the post-chemotherapy specimens, and 6 cases wereassociated with 100% tumor necrosis.</p><p>						<sup>b</sup>MDR-score  &#x02265;2indicates resistance to chemotherapy.</p><p>						<sup>c</sup>McNemar's test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" position="float"><label>Table 6</label><caption><p>Relationships between multiple drug resistance (Pgp expression) in pre-chemotherapybiopsies of 46 osteosarcomas and histological response (necrosis) in surgical specimens<sup>a</sup>. <italic>P</italic><italic> value</italic><sup>b</sup> = .53.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Pre-chemotherapy MDR-score<sup>a</sup></th><th align="center" colspan="2" rowspan="1">Tumor necrosis</th><th align="center" rowspan="2" colspan="1">&#x02211;</th></tr><tr><th align="center" rowspan="1" colspan="1">&#x0003c;90%</th><th align="center" rowspan="1" colspan="1">&#x02265;90%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> &#x02265;2</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003c;2</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02211;</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">46</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>MDR-score  &#x02265;2 indicates resistance to chemotherapy.</p><p>						<sup>b</sup>Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab7" position="float"><label>Table 7</label><caption><p>Analysesof prognostic impact of clinicopathological, categorical variables, grouped asshown in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Survival<sup>a</sup></th><th align="center" rowspan="1" colspan="1">Recurrence<sup>b</sup></th></tr><tr><th align="left" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">116<sup>c</sup></th><th align="center" rowspan="1" colspan="1">107<sup>d</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic>-<italic>values</italic><sup>e</sup></td><td align="center" rowspan="1" colspan="1"><italic>P</italic>-<italic>values</italic><sup>e</sup></td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">.16</td><td align="center" rowspan="1" colspan="1">.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Age<sup>f</sup></td><td align="center" rowspan="1" colspan="1"><bold>.03</bold></td><td align="center" rowspan="1" colspan="1">.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Extent of tumor</td><td align="center" rowspan="1" colspan="1">.91</td><td align="center" rowspan="1" colspan="1">.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of osteosarcoma</td><td align="center" rowspan="1" colspan="1"><bold>.02</bold></td><td align="center" rowspan="1" colspan="1">.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Largest tumor diameter<sup>f</sup></td><td align="center" rowspan="1" colspan="1">.11</td><td align="center" rowspan="1" colspan="1">.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnostic delay<sup>f</sup></td><td align="center" rowspan="1" colspan="1">.30</td><td align="center" rowspan="1" colspan="1">.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of surgical treatment</td><td align="center" rowspan="1" colspan="1">.16</td><td align="center" rowspan="1" colspan="1"><bold>.05</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative chemotherapy</td><td align="center" rowspan="1" colspan="1">.78</td><td align="center" rowspan="1" colspan="1">.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological response to chemotherapy<sup>g</sup></td><td align="center" rowspan="1" colspan="1">.33</td><td align="center" rowspan="1" colspan="1">.48</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>Survivalanalysis based on disease-specific mortality.</p><p>						<sup>b</sup>All kinds ofrecurrences, but patients with persistent, progressive disease after primarytherapy have been deleted from the analyses.</p><p>						<sup>c</sup>One patient,who did not receive preoperative chemotherapy, died from unrelated disease, andhas been censored from the statistical analysis.</p><p>						<sup>d</sup>Six and 4patients, who did not or did receive preoperative chemotherapy, respectively,had persistent, progressive disease after primary treatment, and are excludedfrom the statistical analysis.</p><p>						<sup>e</sup><italic>P</italic>-values as reported from log-rank tests.</p><p>						<sup>f</sup>Analysisbased on a 3-group comparison, divided on the tertiles.</p><p>						<sup>g</sup>Analysisbased on a comparison between patients (showing  &#x02265;90% versus  &#x0003c;90% tumor necrosis, resp.).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab8" position="float"><label>Table 8</label><caption><p>Analysesof prognostic impact of quantitative and semiquantitative immunohistologicalestimates, as obtained from the pretreatment biopsies (number of patientsanalyzed shown in brackets).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Survival<sup>a</sup></th><th align="center" colspan="2" rowspan="1">Recurrence<sup>b</sup></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">no pre-chemotherapy</th><th align="center" rowspan="1" colspan="1">+pre-chemotherapy</th><th align="center" rowspan="1" colspan="1">no pre-chemotherapy</th><th align="center" rowspan="1" colspan="1">+pre-chemotherapy</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" colspan="2" rowspan="1"><italic>P</italic>-<italic>values</italic><sup>c</sup></td><td align="center" colspan="2" rowspan="1"><italic>P</italic>-<italic>values</italic><sup>c</sup></td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">Angiogenesis<sup>d</sup></td><td align="center" rowspan="1" colspan="1">.90</td><td align="center" rowspan="1" colspan="1">.92</td><td align="center" rowspan="1" colspan="1">.23</td><td align="center" rowspan="1" colspan="1">.76</td></tr><tr><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(30)</td><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(35)</td></tr><tr><td align="left" rowspan="2" colspan="1">Proliferation rate (%)</td><td align="center" rowspan="1" colspan="1">.56</td><td align="center" rowspan="1" colspan="1">.52</td><td align="center" rowspan="1" colspan="1">.82</td><td align="center" rowspan="1" colspan="1">.54</td></tr><tr><td align="center" rowspan="1" colspan="1">(70)</td><td align="center" rowspan="1" colspan="1">(46)</td><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(42)</td></tr><tr><td align="left" rowspan="2" colspan="1">Proliferation index (mm<sup>&#x02212;2</sup>)</td><td align="center" rowspan="1" colspan="1">.47</td><td align="center" rowspan="1" colspan="1">.81</td><td align="center" rowspan="1" colspan="1">.43</td><td align="center" rowspan="1" colspan="1">.89</td></tr><tr><td align="center" rowspan="1" colspan="1">(70)</td><td align="center" rowspan="1" colspan="1">(46)</td><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(42)</td></tr><tr><td align="left" rowspan="2" colspan="1">p53 expression (%)</td><td align="center" rowspan="1" colspan="1">.18</td><td align="center" rowspan="1" colspan="1">.29</td><td align="center" rowspan="1" colspan="1">.43</td><td align="center" rowspan="1" colspan="1">.11</td></tr><tr><td align="center" rowspan="1" colspan="1">(70)</td><td align="center" rowspan="1" colspan="1">(46)</td><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(42)</td></tr><tr><td align="left" rowspan="2" colspan="1">p53 index (mm<sup>&#x02212;2</sup>)</td><td align="center" rowspan="1" colspan="1">.73</td><td align="center" rowspan="1" colspan="1">.99</td><td align="center" rowspan="1" colspan="1">.90</td><td align="center" rowspan="1" colspan="1">.90</td></tr><tr><td align="center" rowspan="1" colspan="1">(70)</td><td align="center" rowspan="1" colspan="1">(46)</td><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(42)</td></tr><tr><td align="left" rowspan="2" colspan="1">MDR/Pgp</td><td align="center" rowspan="1" colspan="1">.43</td><td align="center" rowspan="1" colspan="1">.12</td><td align="center" rowspan="1" colspan="1">.23</td><td align="center" rowspan="1" colspan="1">.16</td></tr><tr><td align="center" rowspan="1" colspan="1">(70)</td><td align="center" rowspan="1" colspan="1">(46)</td><td align="center" rowspan="1" colspan="1">(65)</td><td align="center" rowspan="1" colspan="1">(42)</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup>Analysisbased on disease-specific mortality, and for continuous parameters divided onthe median, whereas for MDR/Pgp divided in a chemotherapy-sensitive group(score &#x0003c;2) and a chemotherapy-resistant group (score &#x02265;2).</p><p>						<sup>b</sup>All kinds ofrecurrences, but patients with persistent, progressive disease after primarytherapy have been deleted from the analyses.</p><p>						<sup>c</sup><italic>P</italic>-values as reported from log-rank tests.</p><p>						<sup>d</sup>Angiogenesis could not be estimated in 21 cases due to technical, immunohistological problems,see text.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>